ABPI response to DSIT spending allocations

The Department for Science, Innovation and Technology (DSIT) has today announced funding for research and development, including in life sciences.

In response, ABPI Director of UK Competitiveness and Devolved Nations, Joe Edwards said: “The research and development of new medicines and vaccines is a powerful contributor to economic growth. The pharmaceutical industry is the largest private sector investor in UK R&D, and this strength is built upon a strong foundation of world-class science.

“Public R&D investment is one of government’s most powerful tools to boost growth and increase productivity if directed effectively. Today’s announcements offer welcome clarity for research funders at a time when inflation is putting extra pressure on R&D budgets.

"This funding must be backed up by meaningful long-term action to support discovery science in the upcoming Life Sciences Sector Plan and Comprehensive Spending Review.”

Last modified: 11 April 2025

Last reviewed: 11 April 2025

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.